By merging state-of-the-art drug discovery technologies with profound knowledge of disease biology and a dynamic global business approach, we are propelling forward our unique portfolio of small molecule drug discovery programs along with a variety of research and development collaborations.

Alivexis’ proprietary drug discovery platform, ModBind™, powered by cutting-edge computational science, enables accurate absolute ligand binding predictions at speeds up to 2,000 times faster than conventional methods.

At present, Alivexis is dedicated to swiftly bringing innovative medications to individuals and their families grappling with cancer, both chronic and acute immune-inflammatory conditions, and rare diseases.